Rb influx, in both soleus and plantaris muscles. This activation of cotransporter activity remained relatively constant for up to 10-Hz stimulation for 1 min, falling off at higher frequencies (30-Hz stimulation for 1 min). Similarly, stimulation of skeletal muscle with adrenergic receptor agonists phenylephrine, isoproterenol, or epinephrine produced a dramatic stimulation of NKCC activity. It did not appear that stimulation of NKCC activity was a reflection of increased Na ϩ -K ϩ -ATPase activity because insulin treatment did not stimulate NKCC activity, despite insulin's well-known stimulation of Na ϩ -K ϩ -ATPase activity. Stimulation of NKCC activity could be blocked by pretreatment with inhibitors of mitogen-activated protein kinase (MAPK) kinase 1/2 (MEK1/2) activity, indicating that activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) MAPKs may be required. These data indicate a regulated NKCC activity in skeletal muscle that may provide a significant pathway for potassium transport into skeletal muscle fibers. potassium; electrical stimulation; adrenergic receptor; epinephrine; slow-twitch muscle; fast-twitch muscle; bumetanide; sodium-potassium-adenosinetriphosphatase; ouabain SKELETAL MUSCLE FIBERS must regulate potassium transport to provide a compensatory response to the ion fluxes that occur during contractile activity. Under resting conditions, steady state is maintained by the active transport of potassium into the muscle fiber to compensate losses due to leakage. However, during contractile activity, potassium efflux can exceed potassium influx (30, 42) ; this exacerbated potassium loss is thought to contribute to muscle fatigue (4, 14, 26) . The potassium lost by the muscle accumulates in the extracellular space and the general circulation (26, 30) , but the rapid upregulation of inward transport activity eventually restores intracellular potassium after cessation of contractile activity (12, 37) . The increased inward transport activity must eventually be downregulated to maintain steady state and prevent hypokalemia. In addition to its involvement in potassium homeostasis during contractile activity, inward potassium flux in skeletal muscle is also an important buffering mechanism for ingested potassium. After a meal, ingested potassium could increase plasma potassium to dangerous levels if it were not buffered (25, 43) . Therefore, the mechanisms responsible for inward potassium flux in skeletal muscle are of great interest.
The best-known potassium influx pathway in skeletal muscle is the Na ϩ -K ϩ -ATPase. Na ϩ -K ϩ -ATPase activity can be stimulated by an increase in intracellular sodium (3, 40) and, in some nonmuscle cells, by phosphorylation of its ␣-subunit (2, 3). Contractile activity, increased levels of circulating catecholamines, and increased levels of insulin are known stimulators of Na ϩ -K ϩ -ATPase activity in skeletal muscle (37) . Inwardly rectifying potassium channels may also participate in potassium recovery, but probably only under conditions where locally high extracellular or low intracellular concentrations of potassium shift the equilibrium potential for potassium to values more positive than the resting membrane potential (19, 41) . Another potential mechanism for potassium influx is through the activity of sodium-potassium-chloride cotransporters (NKCC). The regulation of skeletal muscle NKCC activity is the topic of this study.
NKCC activity provides an electroneutral, inwardly directed flux at virtually all physiological ion concentrations and membrane potentials encountered by muscle cells. In skeletal muscle at rest, the activity is low and would not contribute appreciably to net potassium flux (46) . In fact, it has been argued that typical NKCC activity is not present in rat skeletal muscle (9, 10) . However, we have previously reported the expression of NKCC-like proteins in skeletal muscle and found at rest the activity is quite low (46) . Therefore, we were interested in whether NKCC activity could be stimulated, especially by stimuli that are known to increase Na ϩ -K ϩ -ATPase activity in skeletal muscle [e.g., contractile activity, catecholamines, and insulin (7, 15, 37) ]. In addition, we were interested in whether the extracellular-signal regulated kinase 1/2 (ERK1/2) cascade mediates stimulation of NKCC activity, as has been reported for heart muscle after ␣ 1 -adrenergic stimulation (1, 22) . This is a relevant question considering that contractile activity, insulin, and isoproterenol can stimulate the ERK1/2 pathway in muscle (39, 47) .
We report here that epinephrine and contractile activity, but not insulin, stimulate skeletal muscle NKCC activity. The epinephrine-stimulated NKCC activity can be mediated via ␣ 1 -or ␤-adrenergic stimulation. Furthermore, we demonstrate that the intracellular signaling pathway for stimulation of NKCC activity involves activation of the ERK1/2 arm of the mitogenactivated protein kinase (MAPK) pathways.
METHODS
Animal care and muscle preparation. Female SpragueDawley rats (50-100 g) were used for all experiments. Animals were housed in light-and temperature-controlled quarters where they received food and water ad libitum. Animals were randomly assigned to experimental groups, and all animals were handled identically. Animals were anesthetized with pentobarbital sodium (45 mg/kg ip) for tissue removal. Soleus (25-45 mg each) and plantaris muscles (50-90 mg each) were removed by carefully dissecting the proximal tendons at the muscle origin and severing the distal tendon. The muscles were placed in oxygenated KrebsRinger buffer at 25°C in preparation for further treatment (see NKCC activity in skeletal muscle). The integrity of the muscle preparation was verified by the ability of the muscle to elicit a visible unloaded contractile response to a single electrical impulse and, in randomly chosen muscles, the membrane potential of some muscle fibers. Microelectrode measurement of membrane potential indicated intact preparations with initial potentials in a range of Ϫ70 to Ϫ75 mV. In selected muscles, membrane potentials changed by Ϫ0.8 Ϯ 1.6 (SE) and Ϫ1.2 Ϯ 1.7 during 30 min and 2 h of incubation, respectively, in oxygenated Krebs-Ringer solution at 25°C (n ϭ 8 muscles). The Animal Care and Use Committee of the University of Tennessee Health Science Center approved all procedures.
86 Rb influx rate constant calculation. A first-order Michaelis-Menten rate constant for 86 Rb influx into muscle can be calculated if the following assumptions are made: 1) [ 86 Rb] in the bathing is much less than the Michaelis-Menten constant (Km) for the transport processes, 2) the transport of 86 Rb is far from steady state, and 3) steady-state conditions exist for transport intermediates and diffusion processes. In these experiments, the first condition was met by the low concentration of 86 Rb in the solutions used to bathe the muscles (1 Ci/ml 86 Rb at 2-10 nmol Rb/Ci). To determine the transport kinetics and obtain an assay time for the second requirement, we measured the time course of 86 Rb uptake by muscles suspended in oxygenated (95% O2-5% CO2) Krebs-Ringer solution (in mM: 120 NaCl, 25.1 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 1.3 CaCl2, and 10 D-glucose, pH 7.4) at 30°C (Fig. 1) . After incubation, the muscles were rinsed three times, 5 min each in 50 ml Krebs-Ringer solution at 4°C, blotted dry, weighed in tared scintillation vials, and counted as described in NKCC activity in skeletal muscle. The data indicate that a steady state for 86 Rb transport is obtained after 15 min of incubation. To assess the third requirement for calculation of a transport rate constant (steady-state intermediates and diffusion), potassium transport processes in the muscles were blocked by preincubating for 15 min at 30°C in oxygenated Krebs-Ringer solution containing 1 mM ouabain, 10 M bumetanide, 5 mM tetraethylammonium, and 1 mM BaCl 2. The muscle was then transferred to an identical tissue bath containing 86 Rb and allowed to incubate at 30°C for various times, blotted dry, and immediately counted without rinsing (Fig. 1) . Similarly, the rinsing procedure was verified by allowing a 10-min incubation of the treated muscle in the 86 Rb-containing bath followed by rinsing in Krebs-Ringer solution at 4°C for various times before counting (Fig. 1) . From these data it is clear that most of the diffusion of 86 Rb is taking place during the first 2 min of incubation. Thus an incubation time of 10 min in the 86 Rbcontaining solution was chosen for all experiments to minimize the impact of diffusion on the rate constants and avoid being near a steady-state condition for total 86 Rb uptake. The rate constant for 86 Rb transport was calculated based on the rate at which the muscle removes 86 Rb from the bulk bathing solution Fig. 1 . A: uptake of 86 Rb into the soleus muscle at 30°C approached steady state by 15 min of incubation in 86 Rb-containing KrebsRinger solution (vehicle, n ϭ 6 muscles per point). The combination of 1 mM ouabain, 10 M bumetanide, 5 mM tetraethylammonium (TEA), and 1 mM BaCl2 in the incubating solution diminished the uptake of 86 Rb (E) to an amount that is easily washed away within 5 min of washout in ice-cold Krebs-Ringer solution (F). CPM, counts per minute; inset: expanded ordinate scale for diffusion (E) and washout (F) values. B: 86 Rb uptake rate constants calculated from 86 Rb uptake data indicate a large influence of the diffusion during the first 2 min of incubation, whereas incubation longer than 10 min was affected by the approach to steady state. On this basis, 10 min was chosen as the uptake period for calculation of the rate constants. 
ͪ
As can be seen in Fig. 1B , the rate constant for 86 Rb uptake is heavily influenced by diffusion during the first 2 min of incubation, but diffusion becomes much less of a contributor if the incubation period is extended to 10 min. After 10 min, however, the calculated transport rate constant is diminished by the approach to steady state. For this reason we chose 10 min as the period of time over which the transport rate constants were measured. This choice of time point makes no assumption that the stimuli of potassium uptake used in the study produce their maximal effect over this period. Studies using perfused hindlimb models have shown that some stimuli may require longer than 10 min to produce their maximal effect (20, 28) . A major difference between these models and the model reported here is that the perfused hindlimb model is a multicompartment model with unstirred layers near the muscle fibers.
NKCC activity in skeletal muscle. The soleus and plantaris muscles were removed from anesthetized rats and immediately placed in oxygenated Krebs-Ringer solution. A stock solution of 10 Ϫ3 M bumetanide was prepared by dissolving bumetanide in 50% DMSO in Krebs-Ringer solution. The working bumetanide Krebs-Ringer solution was prepared by further diluting the stock bumetanide with Krebs-Ringer solution to a final concentration of 10 Ϫ5 M bumetanide. Krebs-Ringer vehicle was similarly prepared except that bumetanide was omitted. The final concentration of DMSO in the vehicle and bumetanide buffers was 0.5%.
Each soleus and plantaris muscle was attached with 4-0 surgical silk suture to platinum electrodes that lay 2 mm apart. The muscles were mounted at resting length such that contractions would be unloaded (37) . The muscles were preincubated for 15 min at 30°C in preincubation media [oxygenated Krebs-Ringer solution containing bumetanide (10 Ϫ5 M), or in vehicle (DMSO) for the contralateral muscle]. After preincubation, muscles were either electrically stimulated for 1 min with 1-ms pulses, 30 V, at frequencies of either 0, 0.3, 1, 3, 10, or 30 Hz, then incubated for 10 min in incubation media (oxygenated Krebs-Ringer solution containing 1 Ci/ml 86 Rb and either bumetanide or vehicle) at 30°C; or the muscles were taken directly to incubation medium, which contained either 100 U/ml of insulin or epinephrine in the range of 0.1 to 100 nM. In some experiments muscles were treated to both electrical and epinephrine treatment. Muscles were immediately washed with ice-cold 0.9% saline solution. After washing, the muscles were blotted, weighed, and homogenized in 2 ml of 0.3 M trichloroacetic acid. 86 Rb uptake by the muscle was measured by scintillation counting. 86 Rb transport was expressed as a rate constant. The bumetanide-sensitive portion of the rate constant was calculated by subtracting the bumetanide treatment value for the muscle of one hindlimb from the vehicle treatment value of the contralateral muscle. Thus the bumetanide and vehicle treatments were statistically paired.
␣1-And ␤-adrenergic stimulation and blockade. ␣1-and ␤-Adrenergic receptors were specifically stimulated by adding 30 M phenylephrine (␣1-adrenergic receptor agonist) or 30 M isoproterenol (␤-adrenergic receptor agonist) to the bumetanide and vehicle incubation media. The ␤-adrenergic receptor antagonist propranolol was added to the preincubation and incubation media of phenylephrine-treated muscle to block any effects that phenylephrine might have on the ␤-adrenergic receptors. Likewise, the ␣ 1-adrenergic antagonist prazosin was added to the preincubation and incubation media for isoproterenol-treated muscle. Separate experiments were performed to test the specificity of the phenylephrine stimulation. The ␣1-adrenergic antagonist prazosin (50 M) alone, or in combination with the ␤-adrenergic antagonist propranolol (1 M), was added to the preincubation and incubation media of phenylephrine-stimulated muscle. Parallel experiments were done for isoproterenol: propranolol, as well as a combination of propranolol and prazosin, were tested with the isoproterenol-treated muscle. Any effects that prazosin or propranolol had on NKCC activity in the presence of agonists were tested by adding only prazosin or propranolol to the preincubation and incubation media of the unstimulated muscle. The bumetanide-sensitive 86 Rb rate constant was determined as before. In some experiments, muscles were treated with a combination of 30 M phenylephrine and 30 M isoproterenol in the incubation medium.
Potassium content measurement. Potassium content was measured by flame photometry. After 1 min of electrical stimulation (see NKCC activity in skeletal muscle), muscles were removed from the incubation bath and placed in ice-cold Krebs-Ringer solution. The muscles were removed from the stimulating electrodes, blotted dry, and clamp-frozen. Tissue was dried under vacuum until weight did not change. The muscle was digested in 10 vol 1:1:1 water-HNO3-H2SO4 for 24-48 h and diluted with water for flame photometry.
MEK1/2 inhibition. Involvement of MAPK intracellular signaling component MAPK kinase 1/2 (MEK1/2) in the activation of NKCC was tested by preincubating muscles for 15 min in the presence of bumetanide or DMSO vehicle, inhibitors of MEK1/2 (10 M PD-98059 or 0.5 M U-0126), an inactive analog to U-0126 (0.5 M U-0124), or vehicle control (DMSO). Muscles were then either electrically stimulated for 1 min at 10 Hz and then incubated for 10 min in incubation media (Krebs-Ringer solutions with 1 Ci/ml 86 Rb, either the inhibitors or their vehicle control, and bumetanide or DMSO vehicle), or they were stimulated using 30 M isoproterenol or 30 M phenylephrine in the incubation media.
Western blotting of phospho-ERK. Whole muscle was preincubated as described before. Incubation time for stimulation lasted for 5 min and included no 86 Rb in the medium. After incubation, the muscles were placed on ice in ice-cold lysis buffer (10 mM Tris ⅐ HCl, pH 7.4, 5 mM EDTA, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM sodium fluoride, 100 M Na3VO4, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 2 g/ml aprotinin, 2 g/ml leupeptin, 2 g/ml antipain, and 1 g/ml pepstatin A), homogenized with a Teflon pestle, and centrifuged at 4°C for 5 min at 5,000 g. Protein concentration of the supernatant was measured by the bicinchoninic acid assay (Pierce, Rockford, IL). Twentyfive micrograms of protein were mixed with SDS denaturing buffer, warmed to 95°C for 5 min, and electrophoresed on a 10% SDS-PAGE gel. The gels were electroblotted with the semidry blotter from Buchler Instruments (Fairfield, NJ). The membrane was incubated overnight at 4°C in the Western blocking buffer (1.5 mM NaH 2PO4, 8 mM Na2HPO4, 0.15 M NaCl, 0.3% Triton X-100, pH 7.4) supplemented with 3% BSA. Immunologic reactions were performed at room temperature for 1.5 h in blocking buffer containing 1% BSA and the specific antibody. Either the phospho-ERK antibody or the ERK-2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) were used at a 1:1,000 dilution. The membrane was subsequently washed four times for 5 min each with blocking buffer and incubated for 45 min at room temperature with horseradish peroxidase-conjugated goat anti-mouse IgG or goat anti-rabbit IgG secondary antibody (Sigma, St. Louis) in blocking buffer supplemented with 1% BSA. After extensive washing with blocking buffer, the immunocomplexes on the membrane were visualized by chemiluminescent exposure of X-ray film (ECL Plus, Amersham). Bands were quantitated using video densitometry. The extent of ERK phosphorylation was determined by comparing the amount of phosphorylated ERK with the total ERK.
Data analysis and statistics. Comparisons within and among treatments for the rate constant data were made by ANOVA; post hoc comparisons, where appropriate, were made using Dunnett's t-test. Differences between treatments were considered significant at ␣ Ͻ 0.05. The power of the statistical tests was calculated using the G-Power program (11) . Data are reported as means Ϯ SE. 86 Rb transport in skeletal muscle. The basal unstimulated 86 Rb influx rate constant was 0.0158 Ϯ 0.0013 and 0.0144 Ϯ 0.0013 (g/ml)
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Ϫ1 ⅐ min Ϫ1 for the soleus and plantaris muscles, respectively (mean Ϯ SE, n ϭ 6 muscle pairs each). The basal unstimulated bumetanide-sensitive 86 Rb influx rate constant was 0.0013 Ϯ 0.0020 and 0.0013 Ϯ 0.0017 (g/ml) Ϫ1 ⅐ min Ϫ1 for the soleus and plantaris muscles, respectively (n ϭ 6 muscle pairs each). Both the total and the bumetanide-sensitive 86 Rb-rate constants in the soleus and plantaris muscles were significantly increased by electrically stimulated, unloaded twitch contractions in vitro (P Ͻ 0.0001 by ANOVA, Fig. 2) , with the bumetanide-sensitive transport accounting for approximately 20-25% of the total uptake. There was also a significant effect of vehicle or bumetanide treatment on the stimulated muscle (P Ͻ 0.003 by ANOVA, Fig. 2 ). Post hoc analysis indicated a significant increase in the bumetanidesensitive rate constant for the soleus muscle at 0.3-, 1-, 3-,and 10-Hz stimulation and for the plantaris muscle at 10-Hz stimulation (P Ͻ 0.05). There was not a significant effect of stimulation frequency ranging between 0.3 and 30 Hz on the total or bumetanideinsensitive rate constant for either muscle. We measured muscle potassium content immediately after 1 min of 10-Hz stimulation to test whether bumetanide had an effect on muscle potassium levels during stimulation. Compared with paired vehicle-treated controls, bumetanide-treated soleus and plantaris muscle lost potassium during stimulation (23 Ϯ 14 and 30 Ϯ 23 meq/kg dry wt, respectively). This loss was significantly different from the change in potassium content in the unstimulated, bumetanide-treated muscles (P Ͻ 0.02 and P Ͻ 0.01, respectively, for duplicate comparisons among paired samples of 6 muscle pairs, each). In the unstimulated muscles, bumetanide caused an apparent, although not statistically significant, increase in potassium content of the soleus and plantaris muscles by 43 Ϯ 25 and 35 Ϯ 16 meq/kg dry wt, respectively. Stimulation of vehicle-treated muscles caused a Fig. 2 . A: electrical stimulation had a significant effect on soleus muscle in vitro 86 Rb uptake rate constant for both vehicle-and bumetanide-treated muscles (P Ͻ 0.0001, n ϭ 6 muscles per point); there was not a significant interaction between frequency and treatment. The power of the test for detecting 0.5 SD unit differences at P Ͻ 0.05 was 0.98, 0.90, and 0.90 for the effects of treatment, frequency, and interaction, respectively. B: similarly, electrical stimulation also had a significant effect on plantaris muscle in vitro 86 Rb uptake rate constant for both vehicle-and bumetanide-treated muscles (P Ͻ 0.003, n ϭ 6 muscles per point). Again, there was not a significant interaction between frequency and treatment; the power of the test was the same as for the soleus muscle. C: compared with quiescent control muscles (0 Hz), post hoc analysis indicated the bumetanide-sensitive 86 Rb uptake rate constant increased in electrically stimulated soleus and plantaris muscles (P Ͻ 0.05, n ϭ 6 muscle pairs per point, power of 0.93 and 0.99 for soleus and plantaris muscles, respectively).
decrease in potassium content of 21 and 12 meq/kg dry wt in the soleus and plantaris muscles, respectively, from the unstimulated values of 344 Ϯ 30 and 340 Ϯ 13 meq/kg dry wt, respectively. The unstimulated values are consistent with those reported previously (23) .
Inclusion of either phenylephrine or isoproterenol during the 10-min 86 Rb uptake period also increased the bumetanide-sensitive 86 Rb uptake rate constant in the soleus and plantaris muscles. After exposure to phenylephrine (30 M) in the presence of the ␤-adrenergic antagonist propranolol (1 M), the total 86 Rb uptake rate constants in the soleus and plantaris muscles increased from 0.0252 Ϯ 0.0017 and 0.0182 Ϯ 0.0016 (g/ml)
Ϫ1 ⅐ min Ϫ1 to 0.0318 Ϯ 0.0038 and 0.0260 Ϯ 0.0033 (g/ml)
Ϫ1 ⅐ min
Ϫ1
, respectively. The bumetanide-sensitive 86 Rb uptake rate constants in the soleus and plantaris muscles were significantly increased to 0.0072 Ϯ 0.0020 and 0.0056 Ϯ 0.0024 (g/ ml)
, respectively (P Ͻ 0.05, n ϭ 6) (Fig. 3) . The phenylephrine stimulation of the bumetanide-sensitive 86 Rb uptake was blocked by the addition of the ␣ 1 -adrenergic antagonist prazosin (50 M, Fig. 3 ). Similar to phenylephrine treatment, exposure of the muscle to isoproterenol (30 M) in the presence of the ␣ 1 -adrenergic antagonist prazosin increased the total 86 Rb uptake rate constants in the soleus and plantaris muscles from 0.0284 Ϯ 0.0014 and 0.0209 Ϯ 0.0012 (g/ml)
Ϫ1 ⅐ min Ϫ1 to 0.0377 Ϯ 0.0025 and 0.0266 Ϯ 0.0023 (g/ml)
, respectively. The bumetanidesensitive 86 Rb rate constants of the soleus and plantaris muscles were significantly increased to 0.0108 Ϯ 0.0027 and 0.0032 Ϯ 0.0015 (g/ml)
, respectively (P Ͻ 0.05, n ϭ 6 muscle pairs per point, Fig. 3 ). The isoproterenol effect on bumetanide-sensitive 86 Rb uptake was blocked by the ␤-adrenergic antagonist propranolol (1 M, Fig. 3 ). As a control to determine if phenylephrine was working primarily through an ␣ 1 -adrenergic receptor pathway, prazosin alone (no propranolol) was used to block the effects of phenylephrine on bumetanide-sensitive 86 Rb uptake. Similarly, propranolol alone was used to block the effects of isoproterenol on bumetanide-sensitive 86 Rb uptake. The phenylephrine-induced increase in bumetanide-sensitive 86 Rb uptake was blocked by prazosin alone, and this blockade was not significantly different from blocking with the combination of both prazosin and the ␤-adrenergic antagonist propranolol. The isoproterenol-induced increase in bumetanide-sensitive 86 Rb uptake was also blocked by propranolol alone and was not significantly different from blocking with both propranolol and the ␣ 1 -adrenergic antagonist prazosin. In the absence of agonist, neither prazosin nor propranolol, alone or in combination, had an effect on bumetanide-sensitive 86 Rb uptake (n ϭ 6 muscle pairs, power of 0.85 and 0.93 for soleus and plantaris muscle, respectively, for P ϭ 0.05).
Simultaneous treatment with phenylephrine (30 M) and isoproterenol (30 M) significantly increased the bumetanide-sensitive 86 Rb rate constants to 0.0024 Ϯ 0.0017 and 0.0015 Ϯ 0.0009 (g/ml)
(P ϭ 0.0023, n ϭ 6 muscle pairs) for soleus and plantaris muscles, respectively. However, the bumetanidesensitive 86 Rb uptake rate constant was significantly lower in the soleus and plantaris muscles when stimulated with both ␣ 1 -adrenergic and ␤-adrenergic agonists when compared with ␤-adrenergic agonist stimulation (P ϭ 0.0002 and P ϭ 0.01, respectively). These data indicate interference between the two adrenergic receptor-mediated mechanisms. Compared with ␣ 1 -adrenergic stimulation alone, the bumetanide-sensitive 86 Rb uptake rate constant with simultaneous ␣ 1 -and ␤-adrenergic stimulation was not significantly different for either of the muscles (n ϭ 6 muscle pairs per point, power of 0.97 and 0.46 for soleus and plantaris muscle, respectively, for P ϭ 0.05). Fig. 3 . A: ␣1-adrenergic receptor agonist phenylephrine significantly increased the bumetanide-sensitive 86 Rb uptake in both the soleus and plantaris muscles (P ϭ 0.002 and P ϭ 0.01, respectively, n ϭ 6 muscle pairs per point). Propranolol (1 M) was included in the incubation media to prevent cross-reactivity with the ␤-adrenergic receptor. The phenylephrine-stimulated increase was blocked by the ␣1-adrenergic receptor antagonist prazosin (50 M, n ϭ 6 muscle pairs per point, power of 0.87 and 0.63 for soleus and plantaris muscles, respectively, for P ϭ 0.05). Neither prazosin nor propranolol alone or in combination affected the bumetanide-sensitive uptake in vehicle-treated muscle. B: ␤-adrenergic receptor agonist isoproterenol significantly increased the bumetanide-sensitive 86 Rb uptake in both the soleus and plantaris muscles (P ϭ 0.0003 and P ϭ 0.05, respectively, n ϭ 6 muscle pairs per point). Prazosin (50 M) was included in the incubation media to prevent cross-reactivity with the ␣1-adrenergic receptor. The isoproterenol-stimulated increase was blocked by the ␤-adrenergic receptor antagonist propranolol (1 M, n ϭ 6 muscle pairs per point, power of 0.99 and 0.38 for soleus and plantaris muscles, respectively, for P ϭ 0.05). As in A, neither prazosin nor propranolol alone or in combination affected the bumetanide sensitive uptake in vehicle-treated muscle.
Consistent with the ␣ 1 -and ␤-adrenergic agonist data presented above, the bumetanide-sensitive 86 Rb uptake rate constant was increased by epinephrine in a dose-dependent manner for both the soleus and plantaris muscles (Fig. 4) . Exposure to 10 nM epinephrine caused both the soleus and plantaris muscles to reach a maximal rate constant for bumetanide-sensitive 86 Rb uptake stimulation of 0.0032 Ϯ 0.0008 and 0.0018 Ϯ 0.0005 (g/ml)
Ϫ1 ⅐ min Ϫ1 , respectively (P ϭ 0.002 and 0.005 for soleus and plantaris, respectively, n ϭ 6 muscle pairs per point, power of 0.91 and 0.86 for soleus and plantaris muscle, respectively). Stimulation with 1 nM epinephrine immediately after 1-or 10-Hz electrical stimulation did not result in a greater bumetanide-sensitive 86 Rb rate constant than with either electrical stimulation or epinephrine alone (n ϭ 6 muscle pairs per point, power of 0.87 for soleus and plantaris muscle to detect a 1 SD difference at P Յ 0.05).
In contrast with the results for electrical and adrenergic stimulation, insulin did not stimulate the bumetanide-sensitive 86 Rb uptake rate constant in either the soleus or plantaris muscles. Insulin present at 100 U/ml in the 86 Rb uptake bath stimulated the total 86 Rb uptake rate constant in the soleus muscle to 0.0382 Ϯ 0.0015 (g/ml) Ϫ1 ⅐ min Ϫ1 from an unstimulated rate constant of 0.0262 Ϯ 0.0040 (g/ml)
Ϫ1 ⅐ min Ϫ1 . However, the bumetanide-sensitive portion of this rate constant was only Ϫ0.0010 Ϯ 0.0012 (g/ml)
, and this was not significantly different from the value in the untreated control soleus muscles (n ϭ 22 muscle pairs per point, power of 0.99 to detect a 1 SD difference at P Յ 0.05). Similarly, 100 U/ml insulin stimulated the plantaris muscle 86 Rb uptake rate constant from a basal value of 0.0195 Ϯ 0.0017 (g/ml)
to 0.0257 Ϯ 0.0011 (g/ml) Ϫ1 ⅐ min
. As with the soleus muscle, the bumetanide-sensitive portion of the rate constant in plantaris muscle was minuscule [0.0010 Ϯ 0.0007 (g/ml)
Ϫ1 ⅐ min Ϫ1 ] and not significantly different from that of unstimulated muscle (n ϭ 22 muscle pairs per point, power of 0.99 to detect a 1 SD difference at P Յ 0.05). MEK1/2 inhibition and NKCC activity. After treatment of muscle with PD-98059, 50% of the phenylephrine-stimulated, bumetanide-sensitive 86 Rb uptake was abolished in both slow-twitch and fast-twitch skeletal muscle (Fig. 5) . When the more potent MEK1/2 inhibitor U-0126 was used, all of the phenylephrinestimulated, bumetanide-sensitive 86 Rb uptake was abolished (Fig. 5) . U-0124, the inactive analog of U-0126, did not affect the phenylephrine-stimulated, bumetanide-sensitive 86 Rb uptake in soleus or plantaris muscles. PD-98059, as well as U-0126, abolished all of the isoproterenol-stimulated, bumetanide-sensitive 86 Rb uptake in the soleus and plantaris muscles (Fig.  5) . The isoproterenol-stimulated, bumetanide-sensitive 86 Rb uptake was unchanged by the addition of U-0124.
PD-98059 blocked the electrically stimulated, bumetanide-sensitive 86 Rb uptake in the plantaris muscle (Fig. 6 ). PD-98059 was unable to completely block the electrically stimulated, bumetanide-sensitive 86 Rb uptake in the soleus muscle, however; in this case, the bumetanide-sensitive 86 Rb uptake also was not signif- Fig. 4 . Epinephrine increased the bumetanide-sensitive 86 Rb uptake in both the soleus and plantaris muscles in a dose-dependent manner (P ϭ 0.007 and P ϭ 0.02, respectively, n ϭ 6 muscle pairs per point). The normal physiological range for circulating epinephrine is between 1 and 10 nM (stippled area). Compared with the unstimulated muscle, 10 nM epinephrine significantly increased the bumetanidesensitive 86 Rb uptake rate constant in both muscles (P ϭ 0.002 and P ϭ 0.005, respectively, by Dunnett's t-test, power of 0.91 and 0.86 for soleus and plantaris muscle, respectively). 86 Rb uptake in the soleus and plantaris muscles. Muscles were treated with the inhibitor for 15 min before stimulation with the appropriate agonist during a 10-min 86 Rb uptake period. U-0124, the inactive analog of U-0126, did not affect the adrenergic agonist-stimulated values. (* P Ͻ 0.05 relative to the adrenergic agonist-stimulated value, n ϭ 6 muscle pairs per point).
icantly greater than basal bumetanide-sensitive 86 Rb uptake. U-0126 completely blocked the bumetanidesensitive 86 Rb uptake in the electrically stimulated soleus muscle, but blockade of plantaris muscle bumetanide-sensitive uptake by U-0126 treatment was just outside our chosen significance value (P ϭ 0.055, with a ␤ of 0.49). U-0124 did not affect the electrically stimulated, bumetanide-sensitive 86 Rb uptake (cf. Fig. 2) . ERK1/2 phosphorylation. As has been shown by others (32, 35) , adrenergic receptor activation is a relatively weak stimulator of whole tissue or cell immunoreactive ERK1/2 phosphorylation (Fig. 7) . Muscles were stimulated with isoproterenol for 5 min. SDS-PAGE protein blots were probed with an anti-doubly phosphorylated ERK antibody, stripped, and reprobed with an anti-ERK2 antibody to normalize the phosphorylation for ERK expression; data are expressed as the fractional change in phosphorylation in treated muscle compared with its contralateral control. Normalized for total ERK2, isoproterenol-treated soleus and plantaris muscle had 1.23 Ϯ 0.21 and 1.21 Ϯ 0.21 times more phospho-ERK, respectively, than vehicletreated contralateral muscle. Pretreatment with the MEK1/2 inhibitor U-0126 decreased phospho-ERK in isoproterenol-treated soleus and plantaris muscle 0.87 Ϯ 0.06 and 0.78 Ϯ 0.20 times, respectively, compared with isoproterenol-plus U-0124-treated contralateral muscle (U-0124 is the inactive isomer of U-0126). U-0124 had no effect on the level of isoproterenol-induced phosphorylation of ERK (Fig. 7) . Although stimulation of the ERK pathway is necessary for stimulation of the bumetanide-sensitive transport (Figs. 5 and 6 ), at the whole tissue level it is not sufficient. This was demonstrated by an increased ERK1/2 phosphorylation after 5 min of insulin stimulation. Insulin increased phospho-ERK 1.40 Ϯ 0.15 and 1.19 Ϯ 0.17 times in soleus and plantaris muscles, respectively, compared with vehicle-treated contralateral control muscle (Fig. 7) . Nonetheless, insulin was ineffective for stimulating bumetanide-sensitive transport in the muscle.
DISCUSSION
Ion transport by muscle fibers must be regulated to provide a compensatory response to the dynamic movement of ions during contraction (30, 42) . Previously, we demonstrated that NKCC mRNA, protein, and activity are present in adult rat skeletal muscle (46) . However, whether the NKCC activity could be modulated remained a question. From the data presented here, we conclude that NKCC activity can be modulated by some, but not all, of the stimuli that are also known to stimulate Na ϩ -K ϩ -ATPase activity (15) in a manner that is dependent on MAPK pathways. Three major findings provide the support for this conclusion. First, the skeletal muscle bumetanide-sensitive 86 Rb transport activity can be stimulated to levels accounting for as much as 30% of the potassium congener uptake after electrical stimulation of the muscle or exposure of the muscle to epinephrine and its mimetics. Second, unlike the contractile activity or catecholamines, insulin did not stimulate NKCC activity. Finally, MAPK inhibitors blocked stimulation of NKCC activity. We will discuss the significance of these findings in the following paragraphs.
The rate constants for the basal rate of transport reported here allow comparison with previously reported data. Multiplying the rate constant by the potassium concentration in the bathing solution gives an estimate of the maximum rate of potassium transport under basal conditions. These values for total uptake in the ex vivo muscle preparation here [rate constants ranging from 0.015 to 0.030 (g/ml)
Ϫ1 ⅐ min Ϫ1 ] are comparable to values reported for perfused hindlimb with low-flow perfusion (28) and cardiac myocytes in culture (44) . However, the values reported here are less than those measured under similar conditions (9, 10, 36) , the preparations differing primarily in the source of the rats and the method of muscle excision (pentobarbital surgery in this study vs. decapitation). Basal NKCC activity in skeletal muscle is smaller than the activity observed when the muscle is stimulated. In fact, bumetanide treatment of resting skeletal muscle sometimes causes increased 86 Rb influx (as demonstrated by a negative value for the bumetanide-sensitive 86 Rb rate constant), although this is not statistically significant. This trend may be due to an increase in the activity of other inwardly directed potassium channels and transport mechanisms. Analogously, it has been shown by us and by others that the blockade of the Na ϩ -K ϩ -ATPase can stimulate NKCC or other inwardly directed transport activity (8, 38, 46) . Nevertheless, the conclusion from these data is that quiescent muscle has a very low NKCC-mediated inward flux of isotope compared with total inward flux. Rb uptake in the soleus and plantaris muscles. Muscles were treated with the inhibitor for 15 min before stimulation for 1 min at 10 Hz. 86 Rb uptake was determined over the subsequent 10 min. In the plantaris muscle, the decreased activity with U-0126 treatment was significant at P ϭ 0.055 with ␤ ϭ 0.49; for others significance is indicated at the P Ͻ 0.05 level. (* P Ͻ 0.05 relative to the adrenergic agonist-stimulated value, n ϭ 6-11 muscle pairs per point).
Electrical stimulation of the muscles was a powerful stimulator of the bumetanide-sensitive 86 Rb uptake. As few as 18 electrically induced contractions (0.3 Hz for 1 min) were sufficient stimulus to increase the bumetanide-sensitive 86 Rb uptake significantly above basal levels (Fig. 2) . The relative magnitude of the increase in total transport rate is comparable to that reported previously by Everts et al. (13) . In addition, we found that the stimulation of NKCC activity was not frequency dependent. It has previously been suggested that deoxygenation can stimulate NKCC activity in red blood cells (34) ; protons, potassium, and epinephrine are also well-documented stimuli for potassium transport in red blood cells during exercise, apparently through stimulation of both Na ϩ -K ϩ -ATPase and NKCC activity (29) . Although oxygen in our bathing solution was maintained throughout the preparation, contracting muscle consumes oxygen, creating a possible oxygen gradient within the tissue. However, if the stimulation of NKCC activity due to electrical stimulation occurs by hypoxia, the mechanism is either independent of stimulation frequency or the stimulus threshold is very low.
Adrenergic receptor stimulation was a powerful stimulator of the total and bumetanide-sensitive 86 Rb uptake in skeletal muscle. Comparable to values reported by others, adrenergic receptor stimulation increased total uptake by ϳ40% (7). Stimulation with either an ␣ 1 -or ␤-adrenergic receptor agonist significantly increased NKCC activity in skeletal muscle (Fig. 3) . Although ␣-adrenergic receptor-mediated pathways are often thought to oppose ␤-adrenergic receptor-mediated pathways, in some cases their activities do complement each other and activate NKCC activity in some cell types (1, 18, 47) . Defining the specific receptor-mediated pathways responsible for NKCC activation involved pharmacological treatment of the skeletal muscle with the appropriate agonists and antagonists. The results of these experiments indicate that NKCC activity was stimulated specifically by both ␣ 1 -and ␤-adrenergic receptor-mediated pathways. In the case of the ␤-adrenergic receptor-mediated pathway, the bumetanide-sensitive transport accounted for nearly one-third of the total 86 Rb uptake. Furthermore, the maximum NKCC activity stimulated by epinephrine (Fig. 4) was not significantly different from that caused by stimulation with phenylephrine or isoproterenol (P Ͻ 0.05). This may indicate that a maximal level of stimulation of NKCC activity was obtained with either the phenylephrine or isoproterenol and that the ␣ 1 -and ␤-adrenergic receptor-mediated pathways converge to activate NKCC. Such a Fig. 7 . Isoproterenol and insulin modestly increase extracellular signal-regulated kinase 1 (ERK1) and ERK2 phosphorylation. Doubly phosphorylated ERK1 and ERK2 were quantified by Western blot (typical blot shown in A for soleus muscle), and the data were normalized by total ERK2 expression, as determined by stripping and reprobing the Western blots with an anti-ERK2 antibody (not shown). Relative to its vehicletreated control, 10 min exposure of the contralateral muscle to isoproterenol or insulin increased the ERK phosphorylation by 20-40% in the soleus and plantaris muscles (B; n ϭ 5-6 muscle pairs per determination). Exposure of both muscles of each pair to isoproterenol, with one being pretreated with the MEK1/2 inhibitors U-0126 or PD-98059, resulted in the pretreated muscle showing less ERK phosphorylation (C; n ϭ 5-6 muscle pairs per determination). The inactive U-0124 had no effect on ERK phosphorylation levels in response to isoproterenol. [* P Ͻ 0.05 compared with the control level of phosphorylation for either vehicle treatment (B) or isoproterenol treatment without MEK1/2 inhibitor (C)].
convergence would be consistent with the putative Ca 2ϩ and cAMP-mediated stimulation of muscle potassium transport by methylxanthines and papaverine (20, 27, 28) . Our data may also explain part of the reason why potassium uptake by muscle is impaired in patients taking ␤-adrenergic receptor blockers (17) . Furthermore, considering the relatively low ␣ 1 -adrenergic receptor density in skeletal muscle (33) , the demonstration of a potential physiological role for this receptor is a novel result of these experiments.
Both ␣ 1 -and ␤-adrenergic receptor activation were stimulatory for NKCC activity in the muscle. Therefore, we tested the possibility of an interaction between the two adrenergic receptor-mediated pathways. Treatment of the muscle simultaneously with agonists for both receptors resulted in a significant negative interaction for the stimulation of NKCC activity in the predominantly slow-twitch soleus muscle. It is reasonable to conclude that the ␣ 1 -adrenergic pathway inhibits the ␤-adrenergic pathway. This also may explain why soleus muscle NKCC activity declines when treated with high doses of epinephrine (Fig. 4) .
Perhaps the most significant finding presented here is the lack of NKCC stimulation by insulin. As with catecholamines, insulin is a well-known stimulator of potassium uptake by skeletal muscle (15, 21) . In both adipocytes and fibroblasts, insulin stimulates Na ϩ -K ϩ ATPase activity and NKCC (31) . Because skeletal muscle is one of the primary targets of insulin, we tested whether insulin stimulated NKCC activity in muscle.
Although physiological resting levels of insulin in the rat are 10 U/ml, 100 U/ml was used to ensure activation of its receptor. We confirmed that insulin indeed stimulated 86 Rb uptake in both soleus and plantaris muscles. However, the increase in uptake was not due to stimulation of NKCC activity because insulin did not significantly stimulate the bumetanide-sensitive 86 Rb uptake. We conclude that the insulin-stimulated 86 Rb uptake is primarily due to the well-documented stimulation of Na ϩ -K ϩ ATPase activity (6, 15) . Taken with results from catecholamine stimulation and electrical stimulation, these data show that NKCC activity is regulated and stimulated in response to some stimuli, but not by all stimuli known to stimulate potassium uptake by skeletal muscle.
Contractile activity, phenylephrine, and isoproterenol have all been shown to rapidly stimulate MAPK activity (39, 47) . Therefore, we were interested in the potential involvement of MAPK in the stimulation of NKCC activity in skeletal muscle. Specifically, we tested the involvement of the ERK arm of the MAPK pathways. ERK1/2, key substrates in this signal cascade, are activated by phosphorylation by MEK1/2. In our experiments, known inhibitors of MEK1/2 abolished the isoproterenol-stimulated NKCC activity (Fig.  5 ) and the electrically stimulated NKCC activity (Fig.  6) . Phenylephrine-stimulated NKCC activity showed the same trend, although the effect was not as striking (Fig. 5) . From these data, we conclude that the ERK1/2 pathway is necessary for stimulation of NKCC activity in muscle. However, insulin is also known to stimulate the ERK1/2 pathway (Fig. 7 and Ref. 24) , so why does insulin not stimulate NKCC activity in skeletal muscle? One possibility is that ERK1/2 activation alone may not be sufficient to stimulate skeletal muscle NKCC activity. Another possibility is that insulin stimulates a unique subset or compartment of ERK1/2 kinases. It is also possible that insulin activates other intracellular signaling mechanisms (5, 16 ) that may inhibit ERK1/2 activation of skeletal muscle NKCC activity. Unfortunately, no MAPK-specific activators are currently available that will specifically activate the ERK1/2 pathway without stimulating other mechanisms (e.g., tyrosine kinase receptor agonists). Nevertheless, the demonstration by these data of a difference within skeletal muscle in the consequences of stimulating the ERK1/2 pathway through distinctly different mechanisms is a significant finding. Furthermore, NKCC activity in skeletal muscle may prove to be a valuable model to study the interactions of various intracellular signaling pathways.
In conclusion, we have shown that electrical stimulation, ␣ 1 -adrenergic stimulation, and ␤-adrenergic stimulation of muscle increased muscle NKCC activity. The intracellular mechanism responsible for the increased NKCC activity, regardless of stimulus, involved the activation of the ERK1/2 arm of the MAPK pathways. However, complexity in the intracellular signal pathways was evident in that stimulation of the ERK1/2 pathway with insulin did not stimulate NKCC activity. Functionally, the rapid stimulation of NKCC activity in skeletal muscle may serve as an additional potassium sequestering mechanism by muscle cells. This could provide the body with another rapid, efficient mechanism to buffer potassium and may be of particular importance for insulin-independent control of plasma potassium.
Perspectives
We report a mechanism for control of a putative potassium transport process in skeletal muscle: NKCC activity. Potassium transport by skeletal muscle is important for both muscle function and for buffering plasma potassium; bumetanide-sensitive transport in these experiments could account for 20-30% of the total muscle transport. The measurements here were based, in part, on 86 Rb uptake. Two previous reports by Dørup and Clausen (9, 10) have indicated that bumetanide-sensitive 86 Rb may not be indicative of a bumetanide-sensitive 42 K transport. On the other hand, we have previously reported molecular and functional evidence for the expression of NKCC in skeletal muscle (46) . The major differences between these experiments is the source of the animals, the method of tissue removal (decapitation vs. anesthesia), and the use of different radiotracers. Does rat skeletal muscle express an NKCC that discriminates potassium from Rb? Rb generally cosegregates with potassium and has a content in skeletal muscle of ϳ200 M (45) . The data here indicate that NKCC activity is stimulated by contractile activity and catecholamines through specific signal transduction pathways. Because of the ability of Rb to enter cells through many potassium transport mechanisms, it seems unlikely that a separate, regulated transport mechanism would exist for Rb. However, the previous reports of an apparent discrimination between potassium and Rb by NKCC raise a question of just what the bumetanide-sensitive transport is transporting. Only future experiments will give us insight into its function and regulation.
